-
Product Insights
Omicron Consul./ Telus Corp – Nanaimo Rental Community – British Columbia
Equip yourself with the essential tools needed to make informed and profitable decisions with our Omicron Consul./ Telus Corp - Nanaimo Rental Community - British Columbia report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Olverembatinib in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Olverembatinib in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Drug Details:Olverembatinib is a third generation, ponatinib...
-
Product Insights
![]()
Net Present Value Model: IMMBCP-01
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model IMMBCP-01 Drug Details IMMBCP-01 is under...
-
Product Insights
![]()
Net Present Value Model: VLA-2001
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model VLA-2001 Drug Details Coronavirus Disease 2019...
-
Product Insights
![]()
Net Present Value Model: Coronavirus Disease 2019 (COVID-19) vaccines
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Coronavirus Disease 2019 (COVID-19) vaccines Drug...
-
Product Insights
![]()
Net Present Value Model: Xevudy
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Xevudy Drug Details Sotrovimab is a...
-
Product Insights
![]()
Net Present Value Model: Olverembatinib
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Olverembatinib Drug Details Olverembatinib is a...
-
Product Insights
![]()
Net Present Value Model: Comirnaty
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Comirnaty Drug Details Tozinameran (Comirnaty, COVID-19...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – olverembatinib
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry olverembatinib Drug Details Olverembatinib is a third generation, ponatinib analog that acts by targeting...
-
Product Insights
Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Cathepsin L1 plays a major role in antigen processing, tumor invasion and metastasis, bone resorption, and turnover of intracellular and secreted proteins involved in growth regulation. Cathepsin L promotes tumor cell invasion and metastasis by catalyzing the degradation of the interstitial matrix and basement membranes, thus allowing cancer cells to invade locally and metastasize to distant sites. The Cathepsin L1 pipeline market research report provides comprehensive information on the Cathepsin L1 targeted therapeutics, complete with analysis by indications, stage of...
-
Sector Analysis
Occasionwear in Apparel Industry – Analysing Trends, Opportunities and Strategies for Success
The COVID-19 pandemic had a major impact on occasions in 2020 and 2021 as restrictions prevented large gatherings, leading many to postpone their weddings and other special events, and many Christmas parties were cancelled due to the rise of the Omicron variant in December 2021. The easing of restrictions in 2022 has led to a major surge in events as two years' worth of postponed events are finally able to take place, with 61.0% of UK consumers who said they...
-
Product Insights
Severe Acute Respiratory Syndrome (SARS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Severe acute respiratory syndrome (SARS) is a serious, potentially life-threatening viral infection caused by virus from the Coronaviridae family. Symptoms include cough, chills and shaking, headache, muscle aches, diarrhea, dizziness, nausea and vomiting. Risk factors include gene variation in the immune system and close contact with someone who has SARS. The SARS - drugs in development research report provides a comprehensive overview on the therapeutics under development for SARS, complete with analysis by stage of development, drug target, mechanism of...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.